Sector News

CureVac expands vaccine manufacturing with Bayer and GSK

February 5, 2021
Life sciences

CureVac, which is developing an mRNA vaccine for Covid-19, will boost its manufacturing capacity via new agreements with Bayer and GSK.

CureVac already has an agreement with Bayer which will support the development and supply of CureVac’s mRNA candidate CVnCoV. Bayer has now announced that it is planning to manufacture 160m doses of CVnCoV in 2022.

Stefan Oelrich, President of Bayer’s Pharmaceuticals Division, said: “Although we have not previously produced vaccines, we hold strong expertise in the development of biotech products. Since the announcement of our alliance between Bayer and CureVac earlier this year, we have diligently assessed our ability to further contribute with end-to-end manufacturing.

“I am glad to report today that we have the necessary skills and capabilities at Bayer to manufacture CureVac’s mRNA-based vaccine. We are therefore planning to add an additional 160m doses of CureVac’s vaccine in 2022 to further expand their supply network and overall capacity using the manufacturing network of Bayer. First commercial product from this expansion may already be available towards the end of this year.”

CureVac has also announced a new collaboration with GSK to support the manufacture of up to 100m doses of CVnCoV in 2021. In addition, the collaboration aims to develop next generation mRNA Covid-19 vaccines capable of dealing with multiple emerging variants of the virus in the one vaccine. The development programme will start immediately, with a target of 2022 for the multi-variant vaccine.

Franz-Werner Haas, Chief Executive Officer of CureVac, said: “We are very pleased to build on our existing relationship with GSK with a new agreement to jointly develop next generation mRNA-based vaccines, in addition to our current candidate CVnCoV. With the help of GSK’s proven vaccine expertise, we are equipping ourselves to tackle future health challenges with novel vaccines.”

CVnCoV entered phase 3 clinical trials in December and interim data is expected in the first quarter of 2021.

by Amanda Doyle

Source: thechemicalengineer.com

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”